Non-pharmacologic strategies for the management of intestinal inflammation

Inflammatory bowel diseases, irritable bowel syndrome, and mucositis are characterized by intestinal inflammation, but vary according to their pathological mechanisms, severity, location, and etiology. Significant intestinal inflammation that occurs in these diseases induces weight loss, nutritional...

Descripción completa

Detalles Bibliográficos
Autores: Tatiani Uceli Maioli, Luísa Martins Trindade, Aline Souza, Lícia Torres, Maria Emília Rabelo Andrade, Valbert Nascimento Cardoso, Simone de Vasconcelos Generoso
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Institución:Universidade Federal de Minas Gerais (UFMG)
Repositorio:Repositório Institucional da UFMG
Idioma:inglés
OAI Identifier:oai:repositorio.ufmg.br:1843/66060
Acceso en línea:https://doi.org/10.1016/j.biopha.2021.112414
http://hdl.handle.net/1843/66060
https://orcid.org/0000-0002-7538-3208
https://orcid.org/0000-0001-7597-9602
https://orcid.org/0000-0001-6413-8031
Access Level:acceso abierto
Palabra clave:Intestinal inflammation
Omega-3
Probiotic
Prebiotic
Synbiotic
FODMAP
Doenças inflamatórias intestinais
Ácidos graxos Ômega-3
Probióticos
Prebióticos
Simbióticos
Dieta FODMAP
Descripción
Sumario:Inflammatory bowel diseases, irritable bowel syndrome, and mucositis are characterized by intestinal inflammation, but vary according to their pathological mechanisms, severity, location, and etiology. Significant intestinal inflammation that occurs in these diseases induces weight loss, nutritional depletion, and gastrointestinal tract dysfunction. Nutritional support is important in alleviating symptoms and improving patients’ quality of life. In this review, we summarize some nutritional components used to manage intestinal disorders. These include fatty acids, probiotics, parabiotics, postbiotics, prebiotics, synbiotics, and low FODMAP (LFD) diets. These components and LFD diets have been studied and clinical trials have been designed to develop new strategies to alleviate intestinal inflammation and improve the quality of life. Clinical trials on their use in intestinal inflammation do not allow firm conclusions to be drawn mainly because of the heterogeneity of the dose used and the study design or their inconclusive results. However, in the majority of cases, the use of omega-3, probiotics, parabiotics, postbiotics, prebiotics, synbiotics, and LFD improve the health.